Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis

Company Overview

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research programs target biological pathways involved in malignancy and immune-related conditions, with an emphasis on medicines that may address significant unmet medical needs.

Syndax’s lead product, Revuforj (revumenib), is an oral menin inhibitor approved by the U.S. Food and Drug Administration for treating relapsed or refractory acute leukemia with a KMT2A translocation in adults and pediatric patients aged one year and older. The company is also associated with axatilimab, an antibody targeting the colony-stimulating factor 1 receptor (CSF-1R) pathway. Axatilimab, marketed as Niktimvo through a collaboration with Incyte, is approved in the United States for certain adults with chronic graft-versus-host disease after failure of at least two prior systemic therapies.

Founded in 2005 and headquartered in Waltham, Massachusetts, Syndax has historically advanced a pipeline of oncology and immunology candidates through internal research and strategic collaborations. The company is led by Michael A. Metzger, who serves as president and chief executive officer. Its products and development activities are primarily focused on the U.S. market, while its partnerships and clinical programs support broader international development and commercialization efforts.

Key Stats

• Today's Range: $16.39 to $17.29
• 50-Day Range: $16.90 to $20.78
• 52-Week Range: $12.99 to $25.59
• Volume: 2.14 million shs
• Average Volume: 1.88 million shs
• Market Capitalization: $1.50 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.80
• Consensus Rating: Moderate Buy

Syndax Pharmaceuticals Stock Analysis - MarketRank™

Syndax Pharmaceuticals scored higher than 44% of companies evaluated by MarketBeat, and ranked 600th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Syndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Syndax Pharmaceuticals has a consensus price target of $41.80, representing about 147.3% upside from its current price of $16.90.

Amount of Analyst Coverage

Syndax Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($2.03) to ($1.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Syndax Pharmaceuticals is -6.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Syndax Pharmaceuticals is -6.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Syndax Pharmaceuticals has a P/B Ratio of 22.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.49% of the float of Syndax Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 14.73, which indicates bearish sentiment.

Change versus previous month

Short interest in Syndax Pharmaceuticals has recently decreased by 4.71%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Syndax Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Syndax Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.39

News Sentiment

Syndax Pharmaceuticals has a news sentiment score of -0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Syndax Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 4 people have searched for SNDX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Syndax Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.80% of the stock of Syndax Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Syndax Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SNDX
• CIK: 1395937
• Web: www.syndax.com
• Phone: (781) 419-1400
• Fax: 781-419-1420
• Employees: 298
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Syndax Pharmaceuticals: $41.80
• High Price Target: $57.00
• Low Price Target: $33.00
• Potential Upside/Downside: +147.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$285.42 million
• Net Margins: -87.52%
• Pretax Margin: -87.52%
• Return on Equity: -372.94%
• Return on Assets: -39.11%

Debt

• Debt-to-Equity Ratio: 38.95
• Current Ratio: 6.77
• Quick Ratio: 6.44

Sales & Book Value

• Annual Sales: $172.35 million
• Price / Sales: 8.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.74 per share
• Price / Book: 22.84

Miscellaneous

• Outstanding Shares: 88,610,000
• Free Float: 84,357,000
• Market Cap: $1.50 billion
• Optionable: Optionable
• Beta: 0.42